EQS-News

Revolune Announces Commercial Availability of Multiplex Immunofluorescence Reagents 15.06.2026, 14:05 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Revolune / Key word(s): Personnel/Product Launch
Revolune Announces Commercial Availability of Multiplex Immunofluorescence Reagents

15.06.2026 / 14:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


Company enters commercialization phase following successful early access program and appoints Adrian Arechiga as Chief Commercial Officer

OBERKOCHEN, Germany, June 15, 2026 /PRNewswire/ -- Revolune today announced the commercial availability of its multiplex immunofluorescence reagent portfolio and the official start of its commercialization journey. The milestone marks the company's transition from early access to commercial readiness, with reagent solutions designed to support efficient, reproducible, and scalable spatial biology workflows for translational research, biopharma, and biomarker discovery.

Revolune Logo

Spatial biology is becoming increasingly important for understanding tissue architecture, disease mechanisms, and therapeutic response. However, many multiplex tissue analysis workflows remain difficult to implement and scale due to assay complexity, lengthy protocols, and operational burden. Revolune was founded to address these challenges by making multiplex immunofluorescence more accessible for everyday laboratory use.

The company's reagent platform enables researchers to visualize multiple protein biomarkers within intact tissue while leveraging existing primary antibodies and established laboratory practices. By reducing workflow complexity and simplifying assay implementation, Revolune helps laboratories expand multiplexing capabilities without adding significant operational overhead.

Prior to commercialization, Revolune's technology was evaluated through an early access program involving more than 30 laboratories across academic, translational, and biopharmaceutical research environments.

"Today represents an important milestone for Revolune as we enter our commercial phase," said Florian Leiss, Chief Executive Officer of Revolune. "Early access users consistently told us they want the biological insight that multiplexing provides, but not the complexity that often comes with it. Our commercial launch reflects that feedback. We are focused on delivering practical multiplexing solutions that fit naturally into laboratory workflows and allow researchers to spend more time interpreting biology and less time managing assays."

The initial commercial offering supports multiplex protein analysis in preserved tissue samples and is designed for applications in oncology research, translational medicine, and biomarker development. The company plans to continue expanding its portfolio to further support spatial biology research workflows.

As part of its commercial readiness, Revolune also announced the appointment of Adrian Arechiga as Chief Commercial Officer. In this role, Arechiga will lead the company's commercial strategy, and global growth initiatives.

"Researchers need solutions that are scientifically rigorous, but also practical, scalable, and easy to adopt," said Adrian Arechiga, Chief Commercial Officer of Revolune. "Our goal is to help laboratories implement multiplex tissue analysis more efficiently by delivering reagents that simplify workflows and enable researchers to focus on generating meaningful biological results."

About Revolune

Revolune is a life science company dedicated to making multiplex immunofluorescence as accessible and practical as routine tissue analysis. Its reagent technologies are designed to simplify spatial biology workflows, reduce operational complexity, and enable laboratories to focus on biological questions rather than assay management. Revolune supports researchers across oncology, translational medicine, and biopharmaceutical development with scalable multiplex solutions built for real-world laboratory environments.

For more information, visit www.revolune.com 

 

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/revolune-announces-commercial-availability-of-multiplex-immunofluorescence-reagents-302800102.html

rt.gif?NewsItemId=EN83158&Transmission_Id=202606150800PR_NEWS_EURO_ND__EN83158&DateId=20260615


15.06.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2346218  15.06.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News

Gestern 23:20 Uhr • Artikel • dpa-AFX

Gestern 23:20 Uhr • Artikel • dpa-AFX

Gestern 23:18 Uhr • Artikel • dpa-AFX

Gestern 23:06 Uhr • Artikel • dpa-AFX

Gestern 22:38 Uhr • Artikel • dpa-AFX

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer